Arcus Biosciences (RCUS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.72
- Estimate
- -$0.81
- Surprise
- +11.6%
- Revenue (period 2026-06-30)
- $33.0M
- Score today
- 4.0/10
Revenue source: xbrl.
How the report landed
Arcus Biosciences (RCUS) reported a narrower loss than forecast — diluted EPS of -$0.72 against the -$0.81 estimate (a 11.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates RCUS Sell at 4.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +11.6% surprise compares with a +1.8% four-quarter average. Next scheduled report: 2026-10-27.
What argues against it
- Concentration risk — Pipeline: casdatifan
- Concentration risk — Counterparty: Gilead
- Quality below floor (2.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $29.66
- Price target
- $33.35
- Stop
- $27.58
- Upside to target
- +12.4%
- Reward-to-risk
- 1.4:1
Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.
RCUS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.73B
- P/E (fwd)
- -8.9
- 52-week range
- $11.04–$31.73
- Off 52-week high
- 6.5%
- RSI (14)
- 51
- Volume vs avg
- 0.67×
- Score today
- 4.0/10